Related Experiment Video
Updated: Apr 15, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
12.9K
Novel targeted therapies in diffuse large B-cell lymphoma
Neha Mehta-Shah1, Anas Younes1
1Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
Seminars in Hematology
|March 26, 2015
Summary
Diffuse large B-cell lymphoma (DLBCL), an aggressive non-Hodgkin
Area of Science:
- Oncology and Hematology
- Molecular Biology
- Pharmacology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is the most prevalent aggressive form of non-Hodgkin's lymphoma.
- Advances in next-generation sequencing have elucidated key molecular drivers of DLBCL oncogenesis.
- Current treatment strategies face challenges with drug resistance.
Purpose of the Study:
- To review novel therapeutic targets and agents for DLBCL treatment.
- To explore the potential of emerging drugs, including immunomodulatory agents and immunotherapy, in managing DLBCL.
- To discuss synergistic drug combinations for overcoming treatment resistance in DLBCL.
Main Methods:
- Comprehensive literature review of recent advancements in DLBCL therapeutics.
- Analysis of novel drug classes targeting specific molecular pathways in DLBCL.
- Evaluation of immunomodulatory agents and immunotherapy approaches.
Main Results:
- Several novel drug classes are in development for DLBCL.
- Immunotherapy and immunomodulatory agents show promise.
- Combination therapies may enhance efficacy and overcome resistance.
Conclusions:
- Novel therapeutics, including immunotherapy, offer new avenues for DLBCL treatment.
- Targeted therapies and combination strategies are crucial for improving patient outcomes.
- Continued research into molecular pathways is essential for advancing DLBCL management.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
02:57Targeted Cancer Therapies
1.8K
1.8K
01:24Modified-Release Drug Delivery Systems: Site-Targeted
141
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
141
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
02:50Combination Therapies and Personalized Medicine
6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
01:26Targets for Drug Action: Overview
11.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.9K